Pilot Evaluation of a New Urine Progesterone Test to Confirm Ovulation in Women Using a Fertility Monitor
Bouchard et al.
The finding, in our words
A urine progesterone self-test using a 5 μg/mL threshold confirmed ovulation in 82% of cycles, compared with 59% when a 7 μg/mL threshold was used. This pilot study shows that home-based urine testing can reliably detect luteal phase progesterone rise, supporting decentralised fertility monitoring.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
The Mira fertility monitor's LH surge and urine E1-3G levels correlated strongly with the ClearBlue Fertility Monitor's LH surge and low-to-high shift in both postpartum and perimenopause transitions, supporting at-home urine hormone monitoring for fertility tracking.
Bouchard et al., Women's health reports · source ↗
All five at-home urine ovulation predictor kits demonstrated high accuracy (92–97%) when compared with blood LH levels, though sensitivity varied widely from 38% to 77% with Clinical Guard the lowest. Patient experience was comparable across kits, though Clinical Guard was slightly less favoured for future use.
Vanderhoff et al., Fertility and sterility (paywalled) · source ↗
This retrospective case series found that a protocol combining home-based urinary hormone testing with a smartphone application supported fertility management and family planning without unintended pregnancies. The findings suggest that integrating self-collected urinary data with digital tools offers a viable decentralised approach for ovulation prediction.
Leiva & Ecochard, Seminars in reproductive medicine · source ↗
Quantitative at-home urine monitors clearly demarcated luteal phase transitions, luteinisation, progestation, and luteolysis, and identified anovulation across three clinical scenarios. This proof-of-concept suggests self-collected urine hormone measurements could help women target fertility interventions without clinic visits.
Fertility patients commonly use direct-to-consumer ovulation prediction methods, yet reproductive endocrinologists rate the utility of these tests substantially lower than patients do. This discordance highlights the need for better patient education and guidelines to inform self-collection and interpretation of fertility biomarkers in decentralised care.
Peipert et al., Reproductive biomedicine online (paywalled) · source ↗